Antimicrobial prophylaxis in solid-organ transplantation

References

• Singh N. Infectious diseases in the liver transplant recipient. Semin. Gastrointest. Dis. 9,136–146 (1998).
   PubMedGoogle Scholar
• Patel R, Paya CV Infections in solid-organ transplantation recipients. Clin. Microbial Rev. 10,86–124 (1997).
   PubMed Web of Science ®Google Scholar
• •Interesting review on infections in solid-organ transplant (SOT).
   Google Scholar
• Brayman KL, Stephanian E, Matas AJ, et al Analysis of infectious complications occurring after solid-organ transplantation. Arch. Surg 127,38–47 (1992).
   PubMedGoogle Scholar
• Fishman JA, Rubin RH. Infection in organ-transplant recipients N Engl J. Med 338, 1741–1751 (1998).
   PubMed Web of Science ®Google Scholar
• Snydman DR Infection in solid-organ transplantation. Transpl Infict. Dis. 1,21–28 (1999).
   PubMedGoogle Scholar
• Kusne S, Dummer JS, Singh N, et al Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 67,132–143 (1988).
   PubMed Web of Science ®Google Scholar
• Rubin RH. Infectious disease complication of renal transplantation. Kidney Int. 44, 221–236 (1993).
   PubMed Web of Science ®Google Scholar
• ••Defines the three infectious periodspost SOT.
   Google Scholar
• Nicholson V, Johnson C. Infectious complications in solid-organ transplant recipients. Surg. Clin. North Am. 74, 1223–1245 (1994).
   PubMed Web of Science ®Google Scholar
• Peterson PK, Balfour HH, Fryd DS, et al Fever in renal transplant recipients: causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am. J Med 71, 345–351 (1981).
   Google Scholar
• Munoz P. Management of urinary tract infections and lymphocele in renal transplant recipients. Clin. Infict. Dis. 33, S53–557 (2001).
   PubMed Web of Science ®Google Scholar
• Rubin RH. Infection in the organ transplant patient. Third Edition. In: Clinical Approach to Infections in the Immunocompromised Host. Rubin RH, Young LS (Eds). Plenum Medical Book Co., NY, USA (1994).
   Google Scholar
• Richardson WP, Colvin RB, Cheeseman SH, et al Glomerulopathy associated with CMV viremia in renal allograft. N Engl J Med. 305,57–63 (1981).
   PubMed Web of Science ®Google Scholar
• Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin. Infict. Dis. 20,514–520 (1995).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Salvalaggio PR, Topal J, et al Incidence, timing and site of infections among pancreas transplant recipients. J Hy. Infict. 56,184–190 (2004).
   PubMed Web of Science ®Google Scholar
• Pelletier SJ, Crabtree TD, Gleason TG, et al. Characteristics of infectious complications associated with mortality after solid-organ transplantation. Clin. Transplant. 14, 401–408 (2000).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Hermans PE, Rekela J, et al Selective bowel decontamination decrease Gram-negative aerobic bacterial and Candida colonization and prevent infection after ortotopic liver transplantation. Transplantation 45,570–574 (1988).
   PubMed Web of Science ®Google Scholar
• Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am. J Med. 70,405–411(1981).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein—Barr virus infections. Hopes 10(3), 60–65 (2003).
   Google Scholar
• Wiesner RH. The incidence of Gramnegative bacterial and fungal infection in liver transplantation patients treated with selective decontamination. Infiction 18, S19—S21 (1990).
   Google Scholar
• Singh N, Paterson DL, Chang FY, et al Methicillin-resistant Staphylococcus aureus: the other emerging resistant Gram-positive coccus among liver transplant recipients Clin. Infect. Dis. 30,322–327 (2000).
   PubMed Web of Science ®Google Scholar
• •Demonstrates the increasing trend of methicillin-resistant Staphylococcus aureus infections in SOT.
   Google Scholar
• Paterson D, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 75, 194–198 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon SM, LaRosa SP, Kalmadi S, et al Should prophylaxis for Pneumocystis carinii pneumonia in solid-organ transplant recipients ever be discontinued? Clin. Infict. Dis. 2,240–246 (1999).
   Google Scholar
• ••Defines the optimal durationof Przeumocystis carinn pneumonia prophylaxis.
   Google Scholar
• Rubin RH. Prevention of infection in liver transplant recipient. Liver Tram-plant. 2\(Suppl. 1), 89–98 (1996).
   Google Scholar
• Hibberd PL, Tolkoff-Rubin NE, Doran M, et al Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients: a double-blind, randomized controlled trial. Online J Curr Clin. Trials 11,15(1992).
   Google Scholar
• Lumbreras C, Fernandez I, Velosa J, et al. Infectious complications following pancreatic transplantation: incidence, microbiological and clinic characteristics and outcome. Clin. Infect. Dis. 20,514–520 (1995).
   PubMed Web of Science ®Google Scholar
• Waser M, Maggiorini M, Luthy A, et al Infectious complications in 100 consecutive heart transplant recipients. Eur J. Clin.Microbial Infect. Dis. 13,12–18 (1994).
   PubMed Web of Science ®Google Scholar
• Knosalla C, Weng Y, Warnecke H, et al Mycotic aortic aneurysms after orthotopic heart transplantation: a three-case report and review of the literature. J. Heart Lung Transplant. 5 (8), 827–839 (1996).
   PubMed Web of Science ®Google Scholar
• Kramer MR, Marshall SE, Starnes VA, et al Infectious complications in heart-lung transplantation: analysis of 200 episodes. Arch. Intern. Med 153,2010–2016 (2003).
   Google Scholar
• Speich R, van der Bij W Epidemiology and management of infections after lung transplantation. Clin. Infect. Dis. 33, S58—S65 (2001).
   Web of Science ®Google Scholar
• Snell GL, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplantation recipients with cystic fibrosis. Chest 103, 466–471 (1993).
   PubMed Web of Science ®Google Scholar
• Smyth RL, Higenbottam TW, Scott JP, et al Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 49, 735–739 (1990).
   PubMed Web of Science ®Google Scholar
• Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 112, 1160–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid-organ transplant recipients. Transplant. Infect. Dis. 2,22–28 (2000).
   PubMedGoogle Scholar
• Yeldandi V, Laghi F, McCabe MA, et al Aspergillus and lung transplantation. J. Heart Lung Transplant. 14,883–890 (1995).
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds Ashley E, Benjamin DK, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77,232–237 (2004).
   PubMed Web of Science ®Google Scholar
• Minari A, Husni R, Avery RK, et al The incidence of invasive aspergillosis among solid-organ transplant recipients and implications for prophylaxis in lung transplants. Transplant. Infect. Dis. 4, 195–200 (2002).
   PubMedGoogle Scholar
• Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am. Med Assoc. 261,3607–3609 (1989).
   PubMed Web of Science ®Google Scholar
• Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid-organ transplantation (Cochrane rewiew). In: The Cochrane Library. John Wiley & Sons, Ltd. Chichester, UK (2002).
   Google Scholar
• •Documents the effacy of cytomegalovirus (CMV) prophylaxis.
   Google Scholar
• Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid-organ transplant recipients. Clin. Infect. Dis. 32,742–751 (2001).
   PubMed Web of Science ®Google Scholar
• Daly JS, Kopasz A, Anandakrishnan R, et al Strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am. J. Transplant. 2(10), 955–958 (2002).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acydovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 346,69–74 (1995).
   PubMed Web of Science ®Google Scholar
• Conti DJ, Freed BM, Singh P, Gallichio M, Gruber SA. Preemptive ganciclovir therapy in cytomegalovirus seropositive renal transplant recipients. Arch. Surg 130, 1217–1222 (1995).
   PubMed Web of Science ®Google Scholar
• Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibodypositive renal transplant recipients: a randomized controlled trial. Ann. Intern. Med 123,1826 (1995).
   Web of Science ®Google Scholar
• Gane E, Saliba F, VaMecasas GJC, et al Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350,1729–1733 (1997).
   PubMed Web of Science ®Google Scholar
• Gotti E, Suter E, Baruzzo S, Perani V, Moioli F, Remuzzi G. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin. Transplant. 10,550–555 (1996).
   PubMed Web of Science ®Google Scholar
• Kelly JL, Albert RK, Wood DE, Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 59, 1144–1147 (1995).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356,645–649 (2000).
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid-organ transplant recipients. Am. J. Transplant. 4, 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the efficacy and safety ofvalganciclovir in the prevention of CMV.
   Google Scholar
• Ciancio G, Burke GW, Mattiazzi A, et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas—kidney, and pancreas transplantation. Clin. Transplant. 18 (4), 402–406 (2004).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM, et al Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation N EngL J. Med. 340, 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Gilbert C, et al Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients/. Infect. Dis. 1189(9), 1615–1618 (2004).
   Google Scholar
• Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cyomegalovirus infections after heart transplantation. Transplantation 60, 1473–1477 (1995).
   Google Scholar
• George MJ, Snydman DR, Werner BG, et al The independent role of CMV as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am. J. Med. 103,106–113 (1997).
   PubMed Web of Science ®Google Scholar
• McGavin JK, Goa KL.Gancidovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61(8), 1153–1183 (2001).
   PubMed Web of Science ®Google Scholar
• Briegel J, Forst H, Spill B, et al Risk factors for systemic fungal infections in liver transplant recipients. Eur. J. Clin. Microbial. Infect. Dis. 14,375–382 (1995).
   PubMed Web of Science ®Google Scholar
• Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 40,347–353 (1985).
   PubMed Web of Science ®Google Scholar
• Lumbreras C, Cuervas-Mons V, Jara P, et al, Randomized trial of fluconazole versus nistatin for the prophylaxis of Candida infection following liver transplantation. J. Dis. 174,583–588 (1996).
   Google Scholar
• Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131,729–737 (1999).
   PubMed Web of Science ®Google Scholar
• Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo-controlled study. Tram-plantation 59,45–50 (1995).
   Google Scholar
• Singh N, Wagener MM, Marino IR, Gayowski T Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 73,63–67 (2002).
   PubMed Web of Science ®Google Scholar
• Alexander BD. Prophylaxis of invasive mycoses in solid-organ transplantation. Cur,: Opin. Infect. Dis. 15,583–589 (2002).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DR Why prior fluconazole use is associated with an increased risk of invasive mould infection in immunosuppressed host: an alternative hypothesis. Clin. Infect. Dis. 34, 1281–1283 (2002).
   PubMedGoogle Scholar
• Lorf T, Braun F, Ruchel R, et al Systemic mycoses during prophylactical use of liposomial amphotericin B after liver transplantation. Mycoses 42,47–53 (1999).
   PubMed Web of Science ®Google Scholar
• Marino IR, Panarello G, Singh N. Efficacy of Aspergillus galactomannan-directed preemptive therapy for the prevention of invasive aspergillosis in organ transplant TranspL Infect. Dis. 4,226–227 (2002).
   PubMedGoogle Scholar
• Mora-Duarte J, Betts R, Rotstein E, et al Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N EngL J. Med 347 (25),2020-2029 (2002).
   PubMedGoogle Scholar
• Villanueva A, Gotuzzo E, Arathoon EG, et al A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med 113(4), 294–299 (2002).
   PubMed Web of Science ®Google Scholar